UBS reconfirmed its 'Buy' rating for Welltower (WELL), a leading healthcare REIT, reflecting continued confidence from analyst Michael Goldsmith. The investment bank also increased its price target for the stock from $228 to $240. This new target suggests a potential upside of 5.26% from current levels. This positive outlook contrasts with Wall Street's average price target of $219.11 for WELL. However, GuruFocus presents a more cautious view, estimating a potential downside based on its GF Value of $145.60. Despite the differing valuations, UBS's move signals a positive sentiment towards Welltower's future performance.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis